Literature DB >> 6439897

Prophylactic parenteral cephalosporins in surgery. Are the newer agents better?

J T DiPiro, T A Bowden, V H Hooks.   

Abstract

Parenteral prophylactic cephalosporins used in surgery were compared in 17 published studies. Examination of these studies reveals little justification for preference of one cephalosporin over another. For gastrointestinal, obstetrical-gynecologic, or cardiac operations, newer cephalosporins did not result in substantial decreases in adverse postoperative clinical events (eg, wound infections, intra-abdominal and pelvic infections, and endocarditis) when compared with older cephalosporins. There is no evidence that second- or third-generation cephalosporins result in postoperative infection rates lower than with first-generation cephalosporins.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6439897

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  4 in total

Review 1.  Reappraisal of the antistaphylococcal activities of first-generation (narrow-spectrum) and second-generation (expanded-spectrum) cephalosporins.

Authors:  L D Sabath
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

2.  Clinical consequences of development of resistance to third generation cephalosporins.

Authors:  F Follath; E Costa; A Thommen; R Frei; A Burdeska; J Meyer
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

3.  Antimicrobial prophylaxis to prevent surgical site infection in adolescent idiopathic scoliosis patients undergoing posterior spinal fusion: 2 doses versus antibiotics till drain removal.

Authors:  Vijay H D Kamath; Jason Pui Yin Cheung; Kin Cheung Mak; Yat Wa Wong; Wai Yuen Cheung; Keith Dip Kei Luk; Kenneth Man Chee Cheung
Journal:  Eur Spine J       Date:  2016-03-12       Impact factor: 3.134

Review 4.  Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.

Authors:  A Adu; C L Armour
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.